Comment on ‘Clopidogrel Can be An Effective Complementary Prophylactic for Drug-Refractory Migraine with Patent Foramen Ovale’

Abstract

Keywords

Get full access to this article

View all access options for this article.

References

GBD 2016 Headache Collaborators . Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018;17:954–76.doi:10.1016/S1474-4422(18)30322-3http://www.ncbi.nlm.nih.gov/pubmed/30353868

Takagi

, Umemoto

, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of case-control studies of the association of migraine and patent foramen ovale. J Cardiol 2016;67:493–503.doi:10.1016/j.jjcc.2015.09.016http://www.ncbi.nlm.nih.gov/pubmed/26527111

Tariq

, Tepper

, Kriegler

, . Patent foramen ovale and migraine: closing the Debate–A review. Headache 2016;56:462–78.doi:10.1111/head.12779http://www.ncbi.nlm.nih.gov/pubmed/26952049

Guo

, Shi

, Zhu

, . Clopidogrel can be an effective complementary prophylactic for drug-refractory migraine with patent foramen ovale. J Investig Med 2020;68:1250–5.doi:10.1136/jim-2020-001342http://www.ncbi.nlm.nih.gov/pubmed/32848048

Speciali

, Peres

, Bigal

. Migraine treatment and placebo effect. Expert Rev Neurother 2010;10:413–9.doi:10.1586/ern.10.8http://www.ncbi.nlm.nih.gov/pubmed/20187863

Abu-Arafeh

, Hershey

, Diener

H-C

, . Guidelines of the International headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. Cephalalgia 2019;39:803–16.doi:10.1177/0333102419842188http://www.ncbi.nlm.nih.gov/pubmed/30947525

Sacco

, Braschinsky

, Ducros

, . European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 2020;21:76. doi:10.1186/s10194-020-01130-5http://www.ncbi.nlm.nih.gov/pubmed/32546227